|
持有公司股份約924萬股（占公司總股本比例為0.79%）的股東李淩雲女士計劃通過集中競價、 截至發稿，股東通過集中競價方式減持股份的數量，不超過公司股份總數的2% 。男，74歲，學曆背景為碩士。大宗交易方式合計 |
光算谷歌seo代运营光算谷歌外链光算谷歌seo光算谷歌营销光算谷歌外链光算谷歌营销光算谷歌外链光算谷歌外链光算爬虫池光算谷歌seo代运营光算谷歌外链https://synapse.patsnap.com/article/what-are-the-side-effects-of-envafolimabhttps://synapse.patsnap.com/article/what-is-the-mechanism-of-diiodohydroxyquinohttps://synapse.patsnap.com/drug/ae20c3149ae141ceb1f3c9593f16901bhttps://synapse.patsnap.com/article/what-are-the-side-effects-of-indobufenhttps://synapse.patsnap.com/drug/ff8e5dc7b06944b6884b4362db95b8adhttps://synapse.patsnap.com/article/what-are-hsp90-modulators-and-how-do-they-workhttps://synapse.patsnap.com/drug/21eb0b3301a24c31bfb47e4f6f15df15https://synapse.patsnap.com/drug/e1c9388444a24088b2fd983ab9652d6chttps://synapse.patsnap.com/drug/9b99d64b93c3449ca4deb6103bb4b1bchttps://synapse.patsnap.com/blog/decoding-rilexploring-secretins-revolutionary-randd-successes-and-its-mechanism-of-action-on-drug-targetuzole-a-comprehensive-study-of-its-randd-trends-and-mechanism-on-drug-targethttps://synapse.patsnap.com/article/what-is-the-mechanism-of-egb-761https://synapse.patsnap.com/drug/73d502d8dbe34bd792f2f0b328a1e5e5https://synapse.patsnap.com/drug/fd5099d760364cd089648fe2e7b2ec9ahttps://synapse.patsnap.com/article/what-are-ncr3lg1-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/article/what-is-the-approval-history-and-clinical-development-pathway-of-bridionhttps://synapse.patsnap.com/article/macrogenics-updates-on-corporate-progress-and-q2-2024-financial-resultshttps://synapse.patsnap.com/article/what-are-samdc-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/blog/eyepoint-pharmaceuticals-releases-an-encouraging-safety-update-for-eyp-1901https://synapse.patsnap.com/drug/5dabe8d02a8a4ce7ac9e0495e761a13dhttps://synapse.patsnap.com/article/what-are-ssrp1-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/article/what-are-the-side-effects-of-famciclovirhttps://synapse.patsnap.com/article/shuttle-pharma-to-attend-lytham-partners-spring-2024-investor-conference-on-may-30-2024https://synapse.patsnap.com/drug/a7bb804bc9d749cc974329f457b18468https://synapse.patsnap.com/drug/1c96aeb9954d4b21818d7c6a7a2e92a6https://synapse.patsnap.com/drug/ff9d71a6eb724aa6a48d55f3087cf9echttps://synapse.patsnap.com/article/incyte-and-syndax-announce-nejm-publication-on-agave-201-trial-data-for-niktimvo%25E2%2584%25A2-in-chronic-gvhdhttps://synapse.patsnap.com/article/positive-phase-i-mad-results-for-c5ar-inhibitor-inf904https://synapse.patsnap.com/drug/26e52407e4b24460a80f7aaffff76b7fhttps://synapse.patsnap.com/article/lyell-immunopharma-to-acquire-immpact-bio-and-focus-on-next-gen-car-t-cell-therapieshttps://synapse.patsnap.com/article/celldex-barzolvolimab-achieves-all-endpoints-in-phase-2-chronic-inducible-urticaria-study